Table 4.
Incidence of hypertension by cancer type and chemotherapy status.
|
|
Number of patients evaluated |
Incidence of hypertension | |||||
|---|---|---|---|---|---|---|---|
| Moderate hypertension | Severe hypertension | Crisis-level hypertension | |||||
| Number of patients with moderate hypertension | Incidence rate per 100 person-years (95% CI) |
Number of patients with severe hypertension | Incidence rate per 100 person-years (95% CI) |
Number of patients with crisis hypertension | Incidence rate per 100 person-years (95% CI) |
||
| Overall | |||||||
| Total | 25090 | 7420 (29.6%) | 27.26 (18.00–39.59) | 3946 (15.7%) | 12.36 (6.46–21.42) | 1003 (4.0%) | 2.79 (0.53–8.45) |
| Cancer type | |||||||
| Breast | 9049 | 2565 (28.3%) | 18.38 (10.96–28.91) | 1319 (14.6%) | 8.11 (3.53–15.91) | 325 (3.6%) | 1.80 (0.18–6.90) |
| Lung | 6434 | 1799 (28.0%) | 41.42 (29.78–56.11) | 913 (14.2%) | 17.95 (10.63–28.38) | 234 (3.6%) | 4.11 (1.14–10.39) |
| Colorectal | 4018 | 1446 (36.0%) | 35.60 (24.88–49.38) | 830 (20.7%) | 16.92 (9.84–27.12) | 234 (5.8%) | 4.10 (1.14–10.38) |
| Head and neck | 754 | 191 (25.3%) | 34.82 (24.23–48.46) | 102 (13.5%) | 16.43 (9.47–26.51) | 25 (3.3%) | 3.64 (0.91–9.72) |
| Gastric | 386 | 95 (24.6%) | 38.83 (27.59–53.12) | 52 (13.5%) | 18.45 (11.02–29.00) | 18 (4.7%) | 5.57 (1.95–12.47) |
| Ovarian | 763 | 270 (35.4%) | 37.76 (26.69–51.88) | 173 (22.7%) | 20.24 (12.40–31.18) | 49 (6.4%) | 4.79 (1.51–11.37) |
| Cervical | 313 | 83 (26.5%) | 34.17 (23.69–47.72) | 44 (14.1%) | 15.73 (8.94–25.65) | 9 (2.9%) | 2.96 (0.60–8.70) |
| Renal | 548 | 184 (33.6%) | 46.72 (34.29–62.18) | 86 (15.7%) | 17.01 (9.91–27.23) | 21 (3.8%) | 3.68 (0.93–9.78) |
| Melanoma | 751 | 133 (17.7%) | 16.67 (9.66–26.82) | 64 (8.5%) | 7.26 (2.98–14.77) | 18 (2.4%) | 1.92 (0.22–7.10) |
| Prostate | 1596 | 537 (33.6%) | 38.12 (26.99–52.30) | 305 (19.1%) | 18.00 (10.67–28.45) | 61 (3.8%) | 3.06 (0.65–8.86) |
| Connective and other soft tissue | 478 | 117 (24.5%) | 23.02 (14.60–34.54) | 58 (12.1%) | 10.29 (4.99–18.76) | 9 (1.9%) | 1.42 (0.09–6.29) |
|
| |||||||
| During chemotherapy | |||||||
| Total | 13167 | 3647 (27.7%) | 90.07 (72.43–110.70) | 1901 (14.4%) | 40.21 (28.76–54.71) | 478 (3.6%) | 8.98 (4.10–17.06) |
| Cancer type | |||||||
| Breast | 4144 | 1034 (25.0%) | 70.45 (54.97–88.95) | 508 (12.3%) | 30.04 (20.28–42.88) | 112 (2.7%) | 5.98 (2.19–13.04) |
| Lung | 4294 | 1125 (26.2%) | 102.02 (83.19–123.84) | 563 (13.1%) | 44.27 (32.20–59.37) | 142 (3.3%) | 10.15 (4.90–18.58) |
| Colorectal | 2548 | 908 (35.6%) | 104.50 (85.43–126.56) | 515 (20.2%) | 48.58 (35.89–64.30) | 131 (5.1%) | 10.48 (5.13–19.01) |
| Head and neck | 402 | 93 (23.1%) | 131.01 (109.53–155.46) | 46 (11.4%) | 57.17 (43.32–74.04) | 16 (4.0%) | 18.39 (10.97–28.93) |
| Gastric | 190 | 37 (19.5%) | 69.48 (54.11–87.86) | 21 (11.1%) | 36.80 (25.88–50.77) | 10 (5.3%) | 16.34 (9.40–26.41) |
| Ovarian | 588 | 205 (34.9%) | 93.52 (75.53–114.50) | 124 (21.1%) | 49.42 (36.61–65.26) | 37 (6.3%) | 12.38 (6.47–21.44) |
| Cervical | 169 | 39 (23.1%) | 129.39 (108.05–153.70) | 21 (12.4%) | 63.82 (49.13–81.52) | 3 (1.8%) | 7.80 (3.32–15.50) |
| Renal | 172 | 46 (26.7%) | 109.22 (89.70–131.73) | 21 (12.2%) | 38.41 (27.24–52.63) | 11 (6.4%) | 19.54 (11.86–30.33) |
| Melanoma | 100 | 13 (13.0%) | 59.05 (44.95–76.16) | 8 (8.0%) | 36.54 (25.67–50.47) | 3 (3.0%) | 12.51 (6.57–21.61) |
| Prostate | 381 | 115 (30.2%) | 94.43 (76.35–115.51) | 62 (16.3%) | 42.12 (30.37–56.90) | 10 (2.6%) | 5.78 (2.07–12.76) |
| Connective and other soft tissue | 179 | 32 (17.9%) | 63.40 (48.76–81.06) | 12 (6.7%) | 20.24 (12.40–31.17) | 3 (1.7%) | 4.78 (1.50–11.36) |
|
| |||||||
| During the period with no chemotherapy | |||||||
| Total | 22969 | 5057 (22.0%) | 20.89 (12.92–31.97) | 2621 (11.4%) | 9.64 (4.55–17.92) | 619 (2.7%) | 2.09 (0.27–7.36) |
| Cancer type | |||||||
| Breast | 8660 | 1973 (22.8%) | 15.09 (8.46–24.85) | 985 (11.4%) | 6.72 (2.64–14.04) | 250 (2.9%) | 1.58 (0.13–6.54) |
| Lung | 5571 | 971 (17.4%) | 28.77 (19.23–41.38) | 489 (8.8%) | 13.10 (7.00–22.36) | 109 (2.0%) | 2.70 (0.49–8.31) |
| Colorectal | 3576 | 866 (24.2%) | 25.20 (16.34–37.14) | 478 (13.4%) | 12.35 (6.45–21.40) | 133 (3.7%) | 3.11 (0.67–8.93) |
| Head and neck | 673 | 118 (17.5%) | 24.45 (15.74–36.25) | 64 (9.5%) | 12.24 (6.37–21.26) | 9 (1.3%) | 1.58 (0.13–6.55) |
| Gastric | 343 | 69 (20.1%) | 33.34 (22.99–46.74) | 38 (11.1%) | 17.27 (10.11–27.55) | 9 (2.6%) | 3.54 (0.87–9.58) |
| Ovarian | 628 | 158 (25.2%) | 29.67 (19.97–42.43) | 98 (15.6%) | 16.59 (9.59–26.71) | 18 (2.9%) | 2.73 (0.51–8.36) |
| Cervical | 275 | 53 (19.3%) | 25.17 (16.31–37.10) | 28 (10.2%) | 11.66 (5.96–20.53) | 6 (2.2%) | 2.36 (0.36–7.79) |
| Renal | 520 | 153 (29.4%) | 43.19 (31.28–58.14) | 73 (14.0%) | 16.37 (9.42–26.44) | 10 (1.9%) | 1.98 (0.24–7.20) |
| Melanoma | 732 | 124 (16.9%) | 16.08 (9.20–26.08) | 60 (8.2%) | 7.04 (2.84–14.48) | 16 (2.2%) | 1.77 (0.18–6.86) |
| Prostate | 1554 | 475 (30.6%) | 36.43 (25.58–50.34) | 260 (16.7%) | 16.77 (9.73–26.93) | 52 (3.3%) | 2.90 (0.58–8.62) |
| Connective and other soft tissue | 437 | 97 (22.2%) | 21.34 (13.27–32.51) | 48 (11.0%) | 9.59 (4.52–17.86) | 7 (1.6%) | 1.26 (0.06–6.01) |
Moderate hypertension: 150 mm Hg < SBP ≤ 160 mm Hg or 100 mm Hg < DBP ≤ 110 mm Hg. Severe-hypertension: 160 mm Hg < SBP ≤ 180 mm Hg or 110 mm Hg < DBP ≤ 120 mm Hg. Crisis-level hypertension: 180 mm Hg < SBP or 120 mm Hg < DBP.